Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D07SCP
|
||||
| Former ID |
DIB016609
|
||||
| Drug Name |
MMP-12 inhibitors
|
||||
| Synonyms |
MMP-12 inhibitors (inflammatory diseases); MMP-12 inhibitors (inflammatory diseases), Bracco; Matrix metalloproteinase-12 inhibitors (inflammatory diseases), Bracco
|
||||
| Indication | Inflammatory disease [ICD9: 140-229, 147, 173, 573.3, 710-719; ICD10:C11, C44, K75.9, M00-M25] | Investigative | [1] | ||
| Company |
Bracco SpA
|
||||
| Structure |
|
Download2D MOL |
|||
| Canonical SMILES |
c1(ccc(cc1)OC)Oc1ccc(S(=O)(=O)c2c(CC(=O)NO)cccc2)cc1
|
||||
| Target and Pathway | |||||
| Target(s) | MMP-12 | Target Info | Inhibitor | [2] | |
| NetPath Pathway | IL1 Signaling Pathway | ||||
| IL5 Signaling Pathway | |||||
| Pathway Interaction Database | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | ||||
| Reactome | Collagen degradation | ||||
| Degradation of the extracellular matrix | |||||
| WikiPathways | TGF beta Signaling Pathway | ||||
| Degradation of collagen | |||||
| Matrix Metalloproteinases | |||||
| References | |||||
| REF 1 | WO patent application no. 1999042443A1, Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1636). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.